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872Increased Programmed Death-1 Molecule Expression in
Cytomegalovirus Disease and Acute Graft-versus-Host
Disease after Allogeneic Hematopoietic Cell
Transplantation
Ghislaine M. Gallez-Hawkins,1 Lia Thao,1 Joycelynne Palmer,2 Andrew Dagis,2 Xiuli Li,1
Anne E. Franck,1 Bernard Tegtmeier,3 Simon F. Lacey,4 Don J. Diamond,4 Stephen J. Forman,5
John A. Zaia1To study the role of the programmed death-1 molecule (PD-1) in cytomegalovirus (CMV) infection and dis-
ease after allogeneic hematopoietic cell transplantation (HCT), 206 subjects were followed prospectively for
immune response to CMVand assigned to 3 groups based on CMVoutcome. The subjects were analyzed ret-
rospectively for PD-1 expression in cryopreservedCD41 andCD81 T cells collected at days 40, 90, 120, 150,
180, and 360 posttransplantation. HCTrecipients with CMV disease (n5 14) were compared with recipients
with prolongedCMV infection, but noCMVdisease (median duration of infection, 3months; n5 14) andwith
controls with no CMV infection who received similar transplants (n5 22). The CMV disease group had
a significantly higher mean fluorescein intensity of PD-1 in CD41 (P\.05) and CD81 (P\.05) lymphocytes
at all time points studied. PD-1 expression also was significantly elevated in those with severe acute graft-
versus-host disease (aGVHD), including the no-viremia group. The data suggest that PD-1 is induced by
aGVHD even in the absence of CMV infection. This enhanced PD-1 expression during severe aGVHD and
with CMV reactivation could explain the known role of aGVHD as a risk factor for CMV disease.
Biol Blood Marrow Transplant 15: 872-880 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Cytomegalovirus, PD-1, GVHD, Hematopoietic cell Transplant (HCT)INTRODUCTION
The programmed death 1 molecule (PD-1), a
member of the CD28 family, is expressed on T cells
undergoing apoptosis [1]. PD-1 interacts with the
ligands PD-L1 (B7-H1) and PD-L2 (B70DC), mem-
bers of the B7 family, producing negative inhibitory
effects on T cell function [2,3]. Multiple hematopoi-
etic cell types, including CD41 T cells, CD81 T cells,
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6/j.bbmt.2009.03.022express PD-1, and the physiological effects of PD-1
are only beginning to be understood. It is known that
a negative immunoregulatory signal leading to loss of
T cell effector function is similar to other immunoin-
hibitory receptors (eg, CD72, FcgRIIB, KIR), and that
the cytoplasmic PD-1 domain contains similar motifs,
the immunoreceptor tyrosine-based inhibitory motif
and the immunoreceptor tyrosine-based switch motif
[4]. On activation, PD-1 triggers a cellular cascade
involving phosphatases, which counter the kinases
associated with T cell receptor activation pathways,
thereby decreasing T cell activation, cytokine produc-
tion, and, ultimately, T cell function [1,5,6].
The role of PD-1 in graft-versus-host disease
(GVHD) after allogeneic hematopoietic cell transplan-
tation (HCT) has been studied inmousemodels, which
indicate that PD-1 plays a role in tissue-specific
regulation of allogenic responses [7-9]. The role of
PD-1–PD-L1 inTcell–mediated alloreactions appears
to involve interaction with regulatory T (Treg) cells.
PD-1–PD-L1 activation permits a protective effect of
Tregs, which is abrogated with PD-1 blockade [10].
To date, there has been no description of PD-1 expres-
sion during GVHD in humans. Because acute and
Table 1. Patient Demographic for Each Group
NV (n522) PV (n514) CD (n514) P-value
Patient age year
median (range)
46 (21-59) 45 (22-62) 44 (26-64) .97*
Donor age year
median (range)
44 (20-58) 43 (27-64) 39 (19-58) .16*
Donor status
Sibling 16 (73%) 7 (50%) 7 (50%) .27†
Unrelated donor 6 (27%) 7 (50%) 7 (50%)
Hematopoietic progenitor cell source
Bone marrow 5 (23%) 2 (14%) 0 .16†
Peripheral blood 17 (77%) 12 (86%) 14 (100%)
Diagnosis
Lymphoid malignancy 10 (45%) 7 (50%) 6 (43%) .89†
Myeloid malignancy 11 (50%) 6 (43%) 6 (43%)
Other 1 (5%) 1 (7%) 2 (14%)
Conditioning regimen
Myeloablative 14 (64%) 10 (71%) 8 (57%) .73†
Nonmyeloablative 8 (36%) 4 (29%) 6 (43%)
CMV serology
D+/R+ 15 (68%) 10 (71%) 7 (50%) .73†
D+/R- 3 (13%) 1 (7%) 3 (21%)
D-/R+ 4 (18%) 3 (21%) 4 (29%)
NV indicates nonviremia; PV, prolonged Viremia.
*Kruskal-Wallis test.
†Fisher’s exact test or c2-square test.
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are associated with T cell dysfunction, GVHD is con-
sidered a risk factor for viral [11,12] and fungal
infections [13]. In addition, GVHD is treated with
immunosuppressive agents, thus creating iatrogenic
influences that undoubtedly contribute to the risk for
infection. The up-regulation of PD-1 during aGVHD
inHCT recipients could play a role in the pathogenesis
of infection.
The concept of a loss of T cell function during per-
sistent antigenic challenge was observed in a murine
model of persistent lymphocytic choriomeningitis
virus [14,15], and evaluation of this model led to an
investigation of the role of PD-1 expression as amedia-
tor of this T cell dysfunction. Reversal of T cell dys-
function in this model, using antibody to PD-L1,
confirmed the role of PD-1–PD-L1 interaction in
this process [16]. PD-1–associated T cell exhaustion
has been implicated in human immunodeficiency
virus (HIV) infection [17-23], hepatitis C virus (HCV)
infection [24,25], and hepatitis B virus (HBV) infection
[26]. Of note, HIV-infected subjects exhibited elevated
PD-1 expression on some, but not all, HIV tetramer–
specific cells and on Epstein-Barr virus (EBV)–specific
but not cytomegalovirus (CMV) tetramer–specific cells
[20,21], suggesting an antigen and epitope specificity to
the variation in PD-1 induction. However, PD-1 ex-
pression has been shown to be increased in liver trans-
plant recipients with CMV infection and disease [27]
and in renal transplant recipients with CMV viremia
[28].The role of thePD-1 response duringCMV infec-
tion in the HCT setting remains to be determined.PATIENTS AND METHODS
Patients
A total of 206 consecutive allogeneic HCT recipi-
ents who were considered at risk for CMV infection
(based on detection of CMV antibody in donor or
recipient), and who underwent transplantation be-
tween 2001 and 2006, were followed prospectively
for CMV infection and CMV-specific immunity in
CD41 and CD81 T cells at days 40, 90, 120, 150,
180, and 360 days posttransplantation (day 05 day
of stem cell infusion). PD-1 expression was determined
in cryopreserved peripheral blood mononuclear cells
(PBMCs) from HCT recipients documented to have
CMV disease, prolonged CMV viremia, or no CMV
infection. All subjects were enrolled with the approval
of the City of Hope’s Institutional Review Board for
prospective evaluation of CD4 and CD8 immunity
and CMV infection. The Institutional Review Board
also granted permission for further analysis of unused
frozen specimens for PD-1 analysis.
Table 1 summarizes characteristics of theHCT re-
cipients studied for PD-1 expression. HCT recipientswere grouped as follows. The primary group,
designated the CMV disease (CD) group (n5 14),
comprised all subjects with documented CMV disease,
as definedbyLjungman et al. [29]. In all cases, diagnosis
was based on correlation of clinical events and
documentation of CMV in either bronchoalveolar
lavage (BAL) or tissue biopsy specimens by histology
or tissue culture. The second group, the prolonged
viremia (PV) group (n5 14), comprised all subjects
with delayed clearance ofCMVDNA inplasma asmea-
sured by polymerase chain reaction (PCR) assay after
CMVinfection,which required at least 8 positive assays
for CMV DNA in plasma over approximately 3
months. The case control group, designated the non-
viremia (NV) group (n5 22), comprised HCT recipi-
ents who underwent transplantation around the same
time as those in the CD and PV groups and had no
evidence of CMV reactivation after the CMV surveil-
lance period. All other nonviremic subjects from the
2001-2006 study population (n5 30) also were ana-
lyzed for PD-1 as a control for GVHD-related factors
other thanCMVthatmight influencePD-1 expression.CMV Surveillance
CMV surveillance was done twice weekly from day
121 to day 1100 post-HCT, using a shell vial assay.
Preemptive ganciclovir therapy was implemented
based on the presence of a single CMV-positive shell
vial culture [30]. CMV plasma DNA quantitative
PCR (qPCR) was performed on plasma collected
from the same blood specimen using the CMV gB
DNA as an amplification product, as described previ-
ously [31]. Additional CMV surveillance was done be-
yond day 1100 in ‘‘high-risk’’ recipients based on
874 Biol Blood Marrow Transplant 15:872-880, 2009G. M. Gallez-Hawkins et al.clinical management guidelines at City of Hope. Such
high-risk recipients included thosewith persistent lym-
phopenia, with grade II-IV aGVHD, or requiring con-
tinued immunosuppression for anti-GVHD therapy.
PD-1 Assay
Cryopreserved PBMCs were thawed rapidly in
a 37C water bath, washed twice with RPMI 1640
medium supplemented with 10% heat-inactivated
fetal bovine serum, penicillin (100 U/mL), streptomy-
cin (100mg/mL), and L-glutamine (2 mM) and then
centrifuged at 800 rpm for 10 minutes at 5C. Tubes,
containing about 1 million cells each, were used either
with orwithout antigen stimulation (1mLofCMVpp65
PepMix; Jerini, Berlin,Germany), and incubated for 16
to 20 hours overnight at 37C in 5% CO2. The cells
were then stained with antigen-presenting cell (APC)
mouse anti-human CD8, PE mouse anti-human
CD3, APC-Cy7 mouse anti-human CD4, and FITC
mouse anti-human PD-1 (CD279) (BD Pharmingen,
San Diego, CA) for 30 minutes on ice in the dark.
The isotype controls were APC, PE, APC-Cy7, and
FITC-conjugatedmouse IgG1 k isotype (BDPharmin-
gen). The cells were analyzed by fluorescein-activated
cell sorting (FACS) using aFACSCantoflowcytometer
(BDBiosciences, San Jose,CA).Total events (30,000 to
50,000) were recorded using FACSDiva software (BD
Biosciences) and analyzed using FCS Express Version
3.0 (De Novo Software, Los Angeles, CA). The lym-
phocytes were gated from the dotplot defined by side
scatter and forward scatter determine the CD81 and
CD41/PD-11 T cell populations. The mean fluores-
cein intensity (MFI) of PD-1 was defined as the geo-
metric mean of fluorescein within the gated area. This
parameter is a measure of the average level of PD-1
molecule expression on a cell surface.
Intracellular Cytokine Assay
An intracellular cytokine assay of T cells using in-
terferon (IFN)-g as the marker protein was performed
asdescribedpreviously [31],withbrefeldinA (25 mg/mL;
Sigma, St Louis, MO) used to block the release
of IFN-g. After stimulation with either CMV Ag
(Advanced Biotech, Paterson, NJ) for CD4 or pp65
peptides for CD8, the cells were fixed and then stained
with anti-humanCD4, CD8, and IFN-g antibodies for
FACS analysis.
Statistical Analysis
Nonparametric analyses were performed using
GraphPad Prism 5 software (GraphPad, La Jolla,
CA) software. The Kruskal-Wallis test was used to
compare the PD-1 MFI, as well as the number of
PD-1–positive CD41 and CD81 T cells, among the
3 study groups (CD, PV, and NV). A receiver
operating characteristic (ROC) curve was used to de-termine the sensitivity and specificity of the PD-1
MFI patient values across the full range of cutoffs for
positive and negative outcomes for each group. Using
SAS software (SAS Institute, Cary, NC), Cochran-
Mantel-Haenszel c2 tests were performed to assess
whether PD-1 MFI (dichotomized into values\200
and. 200) correlated with outcome parameters, such
as donor/recipient serology and CD41/CD81/IFN-
g1 adaptive immune responses when stratified by
aGVHD grade 0-I versus grade II-IV.RESULTS
Demographic Data
Table 1 summarizes demographic characteristics
of the HCT recipients in the CD, PV, andNV groups.
The groups were similar in terms of median age,
hematopoietic progenitor cell source, myeloablative
versus nonmyeloablative conditioning regimens used,
underlying diagnoses, and pairing of CMV antibody-
positive donors and recipients.
There was no significant difference in CMV infec-
tion between the CD and PV groups; the median time
to first qPCR positivity was 37 days in the CD group
and 35.5 days in the PV group. Among those with at
least 1 positive plasma qPCR assay, 50% had a positive
CMVblood culture by shell vial assay at some time dur-
ing the active surveillance period. The median time to
positiveCMVshell culturewas 87days in theCDgroup
and 56.5 days in the PV group. Within the CD group,
29% had CMVpneumonia and 71% had CMV gastro-
enterocolitis; the median time to disease occurrence
was 108 days post-HCT (range, 28 to 297 days).
As anticipated, the incidenceof aGVHDgrade II-IV
was greater in the CD group (86%) and the PV group
(79%) compared with the NV group (38%) (P5 .006;
c2 test). There was no significant increase in cGVHD
among the 3 groups (Table 2). The CD and PV groups
had more exposure to corticosteroids, as expected be-
cause of their greater severity of aGVHD.Of the 14 sub-
jects in the PV group, 11 were treated with ganciclovir
based on a positive blood culture, 1 was treated prophy-
lactically during a GVHD flareup, and 2 were never
treated, based on persistently negative blood cultures.
The overall survival (OS) rate at 1 year post-HCT was
64% for the CD group, 71% for the PV group, and
96% for the NV group (P5 .007; log-rank test).
CD41/PD-11T Cell Expression in HCT
Recipients with Chronic CMV Infection
and CMV Disease
Figure 1 shows the CD41 T cell PD-1 MFI and
number of CD41/PD-11 T cells/L for the 3 study
groups. The median PD-1 MFI value was approxi-
mately 100 in the PV and NV groups, but exceeded
200 in the CD group. Using the Kruskal-Wallis test
to compare the median MFI values in the 3 groups
Table 2. Univariate Analysis of Outcome in Each Group
(N and % total)
NV (n522) PV (n514) CD (n514) P-value
Acute GVHD
Grade 0-I 14 (62%) 3 (21%) 2 (14%) .006*
Grades II-IV 8 (38%) 11 (79%) 12 (86%)
Steroids (mg/kg), n (%)
None 6 (27%) 0 2 (14%) .01*
0<1 13 (59%) 5 (36%) 9 (64%)
>1+ 3 (14%) 9 (64%) 3 (21%)
Chronic GVHD, n (%)
None 6 (24%) 2(14%) 2 (14%) .62*
Limited 1 (5%) 3 (21%) 2 (14%)
Extensive 15 (71%) 9 (65%) 10 (72%)
PD-1 MFI on CD4+ cells†
< 200 14 (64%) 7 (50%) 1 (7%) .003*
$ 200 8 (36%) 7 (50%) 13 (93%)
PD-1 MFI on CD8+ cells†
< 200 9 (41%) 4 (29%) 0 .02*
$ 200 13 (59%) 10 (71%) 14 (100%)
CD4+/IFN-g+ cells‡
< 1x106 9 (41%) 7 (50%) 7 (50%) .81*
$ 1x106 13 (59%) 7 (50%) 7 (50%)
CD8+/IFN-g+ cells‡
< 1x106 4 (18%) 4 (29%) 1 (7%) .34*
$ 1x106 18 (82%) 10 (71%) 13 (93%)
Overall 1 year survival
0.96 (0.72,0.99) 0.71 (0.41,0.88) 0.64( 0.34,0.83) .007**
GVHD indicated graft-versus-host disease; IFN, interferon; HCT, hema-
topoietic cell transplantation; MFI, mean fluorescein intensity.
*c2 test.
**logrank test.
†Highest MFI during 1 year post-HCT.
‡Highest number of cells during 1 year post-HCT.
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CD and NV groups for days 40, 90, 120, 150, 180
to 360 post-HCT (P ranging from \ .01 to \ .05;
Figure 1A). In contrast, no detectable difference in
MFI was seen between the PV and NV groups. TheNon-Viremic
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Figure 1. PD-1 expression in CD41 T cells in the CD, PV, and NV groups. A
CD41/PD-11 T cells/L at the same time intervals. The median value in each gro
Kruskal-Wallis test comparing the 3 groups at each time interval post-HCT.assay provided the same results whether or not pp65
PepMix was included in the overnight incubation
(data not shown). Of note, the total number of
CD41/PD-11 T cells/L was similar in the 3 groups,
as shown graphically in the scatterplot of values for
each group in Figure 1.
An attempt was then made to assess the predictive
MFI value for the CD group by combining the MFI
values for the PV and NV groups as control values
and comparing them with the values for the CD group
on days 40 and 90 post-HCT (Figure 2). ROC analysis
found that 80%of the CD group subjects had a CD41/
PD-11 T cell MFI .179 at day 40 and. 174.5 at day
90 post-HCT. The ROC curve, shown as sensitivity
(%) versus 100% specificity (%) in Figure 2 (P5 .002
for day 40 and P5 .0002 for day 90 post-HCT), repre-
sents an area under the curve (AUC) equal to 0.84 for
day 40 and 0.90 for day 90 post-HCT.Elevated CD81/PD-11T Cell Expression
Associated with CMV Disease But Not with
Prolonged CMV Infection
CD81/PD-11 T cell expression, as measured by
MFI, differed significantly between the CD group
and the NV group (P\ .05; Kruskal-Wallis test) up
to 1 year post-HCT (Figure 3). The Kruskal-Wallis
test was used to compare the median MFI values of
the 3 groups, and the Dunn posttest was used to com-
pare the difference in the sum of ranks between 2
groups. The results consistently showed a significantly
higher PD-1 MFI in the CD group compared with the
PV and NV groups at all time points. No significant
differences in the total number of CD81 T cellsged Viremia
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Figure 2. ROC analysis of CD41/PD-11 MFI in the NV and PV groups versus the CD group. An MFI scatterplot and ROC curve are shown for each
group at day 40 (A) and day 90 post-HCT (B).
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(Figure 3B). As was the case for CD41 T cells, the
CD group had a higher CD81 T cell PD-1 MFI value
compared with the PV and NV groups.
The predictive value of the CD81/PD-11 MFI
value in the CD group was assessed by ROC analysis
against the combined values of the PV and NV groups
(Figure 4).MFI values. 171 at day 40 and. 158 at day
90 post-HCT were predictive for 80% of the subjects
with CMV disease (P5 .0002 and .002, respectively).PD-1 MFI and Clinical Outcome
To assess whether the PD-1 MFI was affected by
any other factors besides PV and CMV disease, a uni-
variate analysis was conducted, considering the param-
eters aGVHD, steroid administration, cGVHD, and
PD-1 MFI value (Table 2). The PD-1 MFI values
were dichotomized, based on the ROC analysis,
as\200 and. 200. The adaptive immune response
also was used as a risk parameter, dichotomized as
less than and greater than 1 106 CD41 or CD81/
IFN-g cells/L during the first year of the study period.
The occurrence of aGVHD (P5 .006), the use of
steroids (P5 .01), and the PD-1 MFI values for CD41
(P5 .003) andCD81 Tcells (P5 .02)were the only pa-rameters found to affect CMV outcome; the adaptive
immune response was not affected (Table 2).
To test the effect of aGVHD onMFI values in the
3 groups, a Cochran-Mantel-Haenszel test was used to
compare multiple contingency tables. Figure 5 shows,
for both CD41 and CD81 T cells, a general associa-
tion between PD-1 MFI value (\ 200 or. 200) con-
trolling for aGVHD grade 0-I versus grade II-IV.
The P values of .009 for CD41 T cells and .01 for
CD81 T cells indicate a significant association be-
tween PD-1 MFI value and aGVHD grade in the
CD and PV groups. Figure 5 shows the overall per-
centage of subjects with MFI\200 and. 200 by
aGVHD grade (0-I or II-IV). In contrast, analysis us-
ing the Cochran-Mantel-Haenszel test, based on
whether or not subjects achieved. 1  106 CD41 or
CD81/IFN-g cells/L, revealed no association between
PD-1 expression and immunity among the 3 groups
(P5 .76 for CD41 cells and .38 for CD81 cells).
aGVHD and PD-1 Expression
The demographic data presented in Table 2 dem-
onstrate that aGVHD grade II-IV, but not cGVHD,
was significantly associated with both the CD and
PV groups. Assuming that persistent antigenic stimu-
lation somehow leads to enhanced PD-1 expression,
Non-viremic
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Figure 3. PD-1 expression in CD81 T cells in the CD, PV, and NV groups. A, MFI of PD-1 at indicated times post-HCT for each group. B, Number of
CD81/PD-11 T cells/L. The median value in each group is shown as a horizontal line.*P\ .05; **P\ .01; ***P # .001 using the Kruskal-Wallis test
comparing the 3 groups at each time interval post-HCT.
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CD group primarily resulted from the presence of
aGVHD. To dissociate the effects of aGVHD from
those of CMV infection, we evaluated PD-1 expres-
sion in the nonviremic subjects (n5 52) from the orig-
inal cohort of 206 prospectively studied subjects. Of
these 52 subjects, 30 had aGVHD grade 0-I and 22
had aGVHDgrade II-IV. These nonviremic recipients
did not differ from the overall group in terms of me-
dian age, sex, underlying diagnosis, type of transplant,
conditioning regimen, or donor/recipient CMV serol-
ogy. However, the subjects with aGVHD grade II-IV
had significantly higher PD-1 MFI values than those
with aGVHD grade 0-I at days 40 (P5 .014; Mann-
Whitney test) and 90 post-HCT (P5 .001) for
CD41 T cells and at day 90 post-HCT (P5 .01) for
CD81 T cells (Figure 6).DISCUSSION
This study used a cohort of patients prospectively
studied for CMV infection and immunity and then ret-
rospectively tested for PD-1 expression based on the
severity of CMV infection and disease. Based on pub-
lished reports of other chronic viral infections, including
HIV [21-23], HCV [24,25], andHBV infection [26], we
hypothesized that both PV andCDwould be associated
with enhanced PD-1 expression. Our results, however,
indicated that PD-1 expression is not associated with
PV, but is associated with CD and with aGVHD.
In this study, we analyzed CMV-infected subjects
having prolonged CMV infection with no disease as
a separate group, to identify any factors differentfrom those associated with NV or with CD. Neither
PD-11 cell number nor intensity of PD-1 expression
in CD41 or CD81/PD-11 T cells differed signifi-
cantly between the PV and NV groups. Decreased cy-
tokine production in response to viral antigen has been
observed in HIV [20,21] and HCV infections [24,25].
We found no correlation between PD-1 expression
and CMV-specific immunity; however, the PV group
did have significantly more aGVHD than the NV
group and received significantly more corticosteroid
therapy (Table 2). Thus, it is likely that the persistent
CMV infection in the PV group resulted from iatro-
genic immunosuppression, not to PD-1–induced T
cell exhaustion.
In liver organ transplant recipients, higher PD-1
levels have been significantly associated with CMV
disease and viremia, with this increased PD-1 expres-
sion seen in the total population of CD81 cells [32].
Recently, the functional deficiency of CMV-specific
T cells in renal transplant recipients with CMV infec-
tion has been linked to PD-1, with in vitro evidence of
reversal of the cytokine responsiveness with PD-L1
blockade [28]. In our view, however, enhanced PD-1
expression in HCT recipients is not from viremia per
se, because the subjects with chronic CMV did not ex-
hibit elevated PD-1 expression.
It has been postulated that chronic antigen expo-
sure is a requirement for induction of T cell exhaustion
[14-17,20,21]. This inhibitory response in the pres-
ence of chronic antigenic stimulation is presumably
protective, and the absence of PD-1 and the associated
autoimmune diseases [4] suggests a role for PD-1 in
prevention of immunopathology. PD-1 expression
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Figure 4. ROC analysis of CD81/PD-11 MFI in the NV and PV groups versus the CD group. An MFI scatterplot and ROC curve are shown for each
group at day 40 (A) and day 90 post-HCT (B).
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animal models [7,8]. Thus, it is likely that chronic allo-
geneic stimulation would be associated with enhanced
PD-1 expression after HCT. This study is the first to
report significantly higher PD-1 MFI in HCT recipi-
ents with aGVHD. Even when CMV infection was re-
moved from the analysis, the subjects with grade II-IV
aGVHD had significantly higher PD-1 MFI at days
40 and 90 post-HCT in CD41/CD81 lymphocytes
(Figure 6). This different expression of PD-1 during
aGVHD in the NV group was not observed at later
times in the first year after HCT, nor was it50%
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CD41 cells was significantly associated with the tim-
ing and severity of aGVHD, and this is the first dem-
onstration of aGVHD activating PD-1 expression in
HCT in humans. However, this study was not
designed to describe the timing of aGVHD, manage-
ment variations, and the onset or changes in enhanced
PD-1 expression, and the role of PD-1 in the outcome
and severity of GVHD merits further study.
The presence of severe aGVHD was significantly
associated with both PV and CD (Table 1), but en-
hanced PD-1 expression was correlated only with50%
0
50%
>200 44 17 11 16 23 39
<200 28 0 0 10 13 0
NV PV CD NV PV CD
Grade 0-1 Grade 2-3-4
CD8
ntrolling for aGVHD grade 0-I and grade II-IV for each CMV group. MFI
xis. Results of a Cochran-Mantel-Haenszel test between the 2 aGVHD
.01) (B).
No aGVHD
40 90 120 150 180 360
0
200
400
600
800
0
200
400
600
800
A
aGVHD > II
aGVHD > II
40 90 120 150 180 360
B
No aGVHD
40 90 120 150 180 360
0
200
400
600
C
40 90 120 150 180 360
0
200
400
600
D
P
D
-
1
 
M
F
I
 
o
n
 
C
D
4
+
T
 
c
e
l
l
s
P
D
-
1
 
M
F
I
 
o
n
 
C
D
4
+
T
 
c
e
l
l
s
P
D
-
1
 
M
F
I
 
o
n
 
C
D
8
+
T
 
c
e
l
l
s
P
D
-
1
 
M
F
I
 
o
n
 
C
D
8
+
T
 
c
e
l
l
s
Days post-HCT
Days post-HCT
Days post-HCT
Days post-HCT
Figure 6. PD-1 MFI in CD41 and CD81 T cells of NV subjects with or without GVHD. A and C, MFI for patients with GVHD grade 0-I (designated ‘‘no
aGVHD’’). B and D, MFI for patients with GVHD grade II-IV (designated ‘‘aGVHD$ II’’). The Mann-Whitney test was used to establish the association
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II-IV on day 90 post-HCT (P5.01).
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day 40 or 90 post-HCT was predictive of future
CMV disease (see the ROC analysis in Figures 2 and
4). It is interesting to note that the subjects in the CD
group and those in the PV group had differences in
PD-1 expression, but similar rates of severe
aGVHD (86% vs 79%). Thus, aGVHD by itself
does not explain the variation in PD-1 expression
between the CD and PV groups. We analyzed for
CMV donor serostatus and for complicating fungal
or viral infections and found no statistically signifi-
cant differences among the groups. Similarly, we
found no difference among groups for matched un-
related donor status, which might explain greater
GVHD in one group. Additional studies are needed
to clarify the role of aGVHD and host factors that
could contribute to variations in PD-1 expression.
It is known, for example, that variations in splice
patterns of PD-1 mRNA regulate the level of func-
tional PD-1 in the cell [33].
Further studies are needed to test the hypothesis
that PD-1 expression and T cell exhaustion resulting
from aGVHD lead to progressive CMV infection. In
this regard, how best to identify patients at highest
risk for CMV disease after allogeneic HCT remains
unclear. Our data suggest that the mean level of PD-1
expression on CD4 and CD8 cells early post-HCT is
predictive of future CMV disease. A larger study is
needed to validate PD-1 as a biomarker for CMV risk
before PD-1 expression can become a clinically useful
tool for managing patients.ACKNOWLEDGMENTS
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